Promotional Information

This book describes the modifications of DNA methylation in various major human disease groups, including nonneoplastic diseases that could provide a rationale to develop novel therapeutic strategies such as the use of DNA methylation as a potential tool for determining cancer risk.

Table of Contents

1. DNA methylation – Introduction2. DNA methylation and epigenetics biomarkers in cancer3. DNA methylation and epigenetic biomarkers in non-neoplastic diseases4. DNA methylation and environmental factors5. DNA methylation and epidemiology6. DNA methylation and viral infections7. DNA methylation and cancer8. DNA methylation in breast and ovarian carcinoma9. DNA methylation in tumorous multi-drug resistance10. DNA methylation and endocrinology11. DNA methylation in metabolic diseases (obesity, type II diabetes)12. DNA methylation in pituitary diseases13. DNA methylation and development14. DNA methylation in growth retardation15. DNA methylation in cardiology16. DNA methylation and neurology17. DNA methylation in psychiatric diseases (schizophrenia, alcohol and drug abuses)18. DNA methylation in neurodegenerative diseases19. DNA methylation and autoimmunity20. DNA methylation in lymphocyte development21. DNA methylation in stem cell diseases22. DNA methylation and rheumatology – introduction23. DNA methylation in synovial fibroblasts24. DNA methylation in osteoporosis25. Epigenetic therapies26. Demethylation agents (5-azacytidine)27. Methyl donors (s-adenoyl methionine)28. Methylome analysis of complex diseases29. Methylome analysis in cancer30. Methylome analysis in non-neoplastic disease31. Outlook

About the Author

Professor Neidhart is a senior scientist at the Center of Experimental Rheumatology, Centre for Clinical Research, Switzerland.